X4 Pharmaceuticals, Inc. ( XFOR ) is a biopharmaceutical firm built around its main asset, called Mavorixafor. The treatment is commercially branded as Xolremdi, and it's approved in the US for WHIM syndrome. It's also in the process of expanding toMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busine ...

公司核心资产与适应症 - X4 Pharmaceuticals Inc 是一家专注于其主要资产Mavorixafor的生物制药公司 [1] - 该疗法在美国获批用于治疗WHIM综合征 商品名为Xolremdi [1] - 公司正在推进该疗法向其他适应症扩展 [1] 文章作者背景 - 文章作者Myriam Hernandez Alvarez拥有电子与通信工程学士学位 计算机科学硕士学位 商业管理研究生学位以及计算机应用博士学位 [1] - 作者与另一位Seeking Alpha作者Edgar Torres H有专业合作 但分析独立进行 [1]